Pfizer Inc. (NYSE:PFE) Shares Bought by Farmers Trust Co.

Share on StockTwits

Farmers Trust Co. grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 0.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 177,566 shares of the biopharmaceutical company’s stock after acquiring an additional 690 shares during the period. Pfizer comprises about 1.8% of Farmers Trust Co.’s investment portfolio, making the stock its 13th biggest holding. Farmers Trust Co.’s holdings in Pfizer were worth $6,957,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Sheets Smith Wealth Management lifted its position in shares of Pfizer by 0.6% during the third quarter. Sheets Smith Wealth Management now owns 47,993 shares of the biopharmaceutical company’s stock worth $1,724,000 after purchasing an additional 272 shares during the last quarter. Tradition Asset Management LLC lifted its position in shares of Pfizer by 1.6% during the third quarter. Tradition Asset Management LLC now owns 17,878 shares of the biopharmaceutical company’s stock worth $642,000 after purchasing an additional 274 shares during the last quarter. Liberty Wealth Management LLC lifted its holdings in Pfizer by 3.4% in the third quarter. Liberty Wealth Management LLC now owns 8,470 shares of the biopharmaceutical company’s stock worth $304,000 after acquiring an additional 278 shares during the last quarter. First Heartland Consultants Inc. lifted its holdings in Pfizer by 2.5% in the third quarter. First Heartland Consultants Inc. now owns 11,435 shares of the biopharmaceutical company’s stock worth $411,000 after acquiring an additional 281 shares during the last quarter. Finally, Thomasville National Bank lifted its holdings in Pfizer by 0.4% in the fourth quarter. Thomasville National Bank now owns 82,248 shares of the biopharmaceutical company’s stock worth $3,223,000 after acquiring an additional 290 shares during the last quarter. Institutional investors own 70.21% of the company’s stock.

A number of equities analysts have issued reports on the stock. Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 target price on the stock in a report on Tuesday, October 1st. Bank of America assumed coverage on shares of Pfizer in a report on Wednesday, October 16th. They issued a “neutral” rating and a $37.00 target price on the stock. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Pfizer in a report on Tuesday, October 29th. ValuEngine raised shares of Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, Credit Suisse Group reissued a “hold” rating and issued a $41.30 target price on shares of Pfizer in a report on Wednesday, November 6th. Nine analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $43.41.

Shares of NYSE PFE opened at $40.67 on Thursday. The company has a quick ratio of 0.68, a current ratio of 0.90 and a debt-to-equity ratio of 0.55. The firm’s 50-day moving average price is $38.90 and its two-hundred day moving average price is $38.18. Pfizer Inc. has a 52-week low of $33.97 and a 52-week high of $44.56. The stock has a market capitalization of $221.75 billion, a P/E ratio of 13.56, a P/E/G ratio of 4.24 and a beta of 0.65.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.13. The company had revenue of $12.68 billion for the quarter, compared to analysts’ expectations of $12.37 billion. Pfizer had a return on equity of 28.10% and a net margin of 30.57%. The business’s revenue for the quarter was down 4.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.78 earnings per share. As a group, equities research analysts expect that Pfizer Inc. will post 2.97 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 31st will be issued a dividend of $0.38 per share. This represents a $1.52 dividend on an annualized basis and a dividend yield of 3.74%. The ex-dividend date is Thursday, January 30th. This is a boost from Pfizer’s previous quarterly dividend of $0.36. Pfizer’s payout ratio is 48.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: What is included in the gross domestic product?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.